Oct 2001;77(2-3):203-8
Zepbound demonstrated 20.9% mean body weight reduction in SURMOUNT-1 at 15mg surpassing semaglutides 15% benchmark and establishing dual GIP/GLP-1 agonism as the dominant next-generation obesity mechanism
More realistic estimate: late 2027, with the drug available at pharmacies in early 2028
Key ones include: Magnesium citrate (200-400 mg daily): Helps prevent constipation, supports sleep quality, and reduces muscle cramps B12 or methylcobalamin: GLP-1 agonists can reduce B12 absorption over time, and some compounded formulations include B12 in the compound for this reason Electrolytes: Sodium, potassium, and magnesium supplementation helps offset the dehydration risk from reduced food intake Protein powder: A practical way to maintain protein targets when appetite makes eating full meals difficult Some compounded formulations include additional ingredients like glycine , niacinamide , or glycine plus B12 combinations
Although promising, long-term studies and clinical trials are needed to fully understand GLP-1s impact on the brain
A comprehensive multivitamin provides baseline coverage for vitamins and minerals you might otherwise miss